nach oben

Clinical Autonomic Research

Erschienen in:

09.11.2017 | Review

Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management

verfasst von: Ryuji Sakakibara, Fuyuki Tateno, Tatsuya Yamamoto, Tomoyuki Uchiyama, Tomonori Yamanishi

Erschienen in: Clinical Autonomic Research | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

Parkinson’s disease (PD) and multiple system atrophy (MSA) are major neurogenerative diseases characterized pathologically by abnormal alpha-synuclein aggregation. PD and MSA are clinically characterized by motor disorder and bladder dysfunction (mainly urinary urgency and frequency, also called overactive bladder). However, few literatures are available concerning bladder dysfunction in PD or MSA.

Method

A systematic review.

Results

The bladder dysfunction in MSA is more severe than that in PD for large post-void residual or urinary retention. These bladder dysfunctions presumably reflect the different nervous system pathologies. Overactive bladder in PD reflects lesions in the brain, e.g., in the prefrontal-nigrostriatal D1 dopaminergic bladder-inhibitory pathway. Overactive bladder in MSA reflects lesions similar to PD and the cerebellum (bladder-inhibitory), and the urinary retention in MSA presumably reflects lesions in the pontine micturition center and the sacral intermediolateral nucleus of the spinal cord (bladder-facilitatory). Bladder dysfunction not only impairs an individual’s quality of life, it can also cause emergency hospitalizations due to acute retention and early institutionalization. Anticholinergics are the first-line treatment for bladder dysfunction in PD and MSA patients, but care should be taken for the management of bladder dysfunction—particularly in MSA patients due to the high prevalence of difficult emptying, which needs clean, intermittent catheterization.

Conclusions

This review summarizes the epidemiology, pathophysiology, and management of bladder dysfunction in individuals with PD or MSA.

Goedert M, Jakes R, Spillantini MG (2017) The synucleinopathies: twenty years on. J Parkinsons Dis 7:S53–S71PubMed

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRefPubMed

Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676CrossRefPubMedPubMedCentral

Kikuchi A, Takeda A, Okamura N, Tashiro M, Hasegawa T, Furumoto S et al (2010) In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole positron emission tomography in multiple system atrophy. Brain 133:1772–1778CrossRefPubMed

Tateno F, Sakakibara R, Ogata T, Kishi M, Tsuyusaki Y, Takahashi O, Sugiyama M, Tateno A (2015) Lower urinary tract function in dementia with Lewy bodies (DLB). Mov Disord 30:411–415CrossRefPubMed

Cooper CA, Chahine LM (2016) Biomarkers in prodromal Parkinson disease: a qualitative review. J Int Neuropsychol Soc 22:956–967CrossRefPubMed

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Consortium on DLB et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872CrossRefPubMed

Stanzani-Maserati M, Gallassi R, Calandra-Buonaura G, Alessandria M, Oppi F, Poda R, Sambati L, Provini F, Cortelli P (2014) Cognitive and sleep features of multiple system atrophy: review and prospective study. Eur Neurol 72:349–359CrossRefPubMed

Ozawa T, Revesz T, Paviour D, Lees AJ, Quinn N, Tada M, Kakita A, Onodera O, Wakabayashi K, Takahashi H, Nishizawa M, Holton JL (2012) Difference in MSA phenotype distribution between populations: genetics or environment? J Parkinsons Dis 2:7–18PubMed

10.

Sakakibara R, Tateno F, Nagao T, Yamamoto T, Uchiyama T, Yamanishi T, Yano M, Kishi M, Tsuyusaki Y, Aiba Y (2014) Bladder function of patients with Parkinson’s disease. Int J Urol 21:638–646CrossRefPubMed

11.

Ogawa T, Sakakibara R, Kuno S, Ishizuka O, Kitta T, Yoshimura N (2017) Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. Nat Rev Urol 14:79–89CrossRefPubMed

12.

Sakakibara R (2015) Lower urinary tract dysfunction in patients with brain lesions. Handb Clin Neurol 130:269–287CrossRefPubMed

13.

Sakakibara R, Uchiyama T, Yamanishi T, Kishi M (2009) Sphincter EMG as a diagnostic tool in autonomic disorders. Clin Auton Res 19:20–31CrossRefPubMed

14.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A, Standardisation Sub-committee of the International Continence Society (2002) The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178CrossRefPubMed

15.

Sakakibara R, Panicker J, Fowler CJ, Tateno F, Kishi M, Tsuyusaki Y, Yamanishi T, Uchiyama T, Yamamoto T, Yano M (2014) Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol 21:33–38CrossRefPubMed

16.

Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, Hattori T (2001) Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci 92:76–85CrossRefPubMed

17.

Araki I, Kuno S (2000) Assessment of voiding dysfunction in Parkinson’s disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 68:429–433CrossRefPubMedPubMedCentral

18.

Takahashi O, Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Aiba Y, Yano H, Sugiyama M, Yamamoto T, Yamanishi T, Uchiyama T, Shibata C, Tomaru T (2014) Overactive bladder may precede motor disorder in Parkinson’s disease: a urodynamic study. Parkinsonism Relat Disord 20:1030–1032CrossRefPubMed

19.

Sakakibara R, Hattori T, Uchiyama T, Yamanishi T (2001) Videourodynamic and sphincter motor unit potential analyses in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 71:600–606CrossRefPubMedPubMedCentral

20.

Terayama K, Sakakibara R, Ogawa A, Haruta H, Akiba T, Nagao T, Takahashi O, Sugiyama M, Tateno A, Tateno F, Yano M, Kishi M, Tsuyusaki Y, Uchiyama T, Yamamoto T (2012) Weak detrusor contractility correlates with motor disorders in Parkinson’s disease. Mov Disord 27:1775–1780CrossRefPubMed

21.

Liu Z, Uchiyama T, Sakakibara R, Yamamoto T (2015) Underactive and overactive bladders are related to motor function and quality of life in Parkinson’s disease. Int Urol Nephrol 47:751–757CrossRefPubMed

22.

Yamamoto T, Sakakibara R, Uchiyama T, Liu Z, Ito T, Awa Y, Yamanishi T, Hattori T (2006) Neurological diseases that cause detrusor hyperactivity with impaired contractile function. Neurourol Urodyn 25:356–360CrossRefPubMed

23.

Tsunoyama K, Sakakibara R, Yamaguchi C, Uchiyama T, Yamamoto T, Yamanishi T, Takahashi O, Sugiyama M, Kishi M, Ogawa E (2011) Pathogenesis of reduced or increased bladder sensation. Neurourol Urodyn 30:339–343CrossRefPubMed

24.

Fowler CJ, Griffiths D, de Groat WC (2008) The neural control of micturition. Nat Rev Neurosci 9:453–466CrossRefPubMedPubMedCentral

25.

Sakakibara R, Nakazawa K, Shiba K, Nakajima Y, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2002) Firing patterns of micturition-related neurons in the pontine storage center in cats. Auton Neurosci 99:24–30CrossRefPubMed

26.

Fowler CJ, Griffiths DJ (2010) A decade of functional brain imaging applied to bladder control. Neurourol Urodyn 29:49–55PubMed

27.

Sakakibara R, Tsunoyama K, Takahashi O, Sugiyama M, Kishi M, Ogawa E, Uchiyama T, Yamamoto T, Yamanishi T, Awa Y, Yamaguchi C (2010) Real-time measurement of oxyhemoglobin concentration changes in the frontal micturition area: an fNIRS study. Neurourol Urodyn 29:757–764CrossRefPubMed

28.

Sakakibara R, Nakazawa K, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2002) Micturition-related electrophysiological properties in the substantia nigra pars compacta and the ventral tegmental area in cats. Auton Neurosci 102:30–38CrossRefPubMed

29.

Yamamoto T, Sakakibara R, Nakazawa K, Uchiyama T, Shimizu E, Hattori T (2009) Effects of electrical stimulation of the striatum on bladder activity in cats. Neurourol Urodyn 28:549–554CrossRefPubMed

30.

Sakakibara R, Nakazawa K, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2003) Effects of subthalamic nucleus stimulation on the micturation reflex in cats. Neuroscience 120:871–875CrossRefPubMed

31.

Kitta T, Chancellor MB, de Groat WC, Kuno S, Nonomura K, Yoshimura N (2012) Suppression of bladder overactivity by adenosine A2A receptor antagonist in a rat model of Parkinson disease. J Urol 187:1890–1897CrossRefPubMed

32.

Kitta T, Kakizaki H, Furuno T, Moriya K, Tanaka H, Shiga T, Tamaki N, Yabe I, Sasaki H, Nonomura K (2006) Brain activation during detrusor overactivity in patients with Parkinson’s disease: a positron emission tomography study. J Urol 175:994–998CrossRefPubMed

33.

Yamamoto T, Sakakibara R, Nakazawa K, Uchiyama T, Shimizu E, Hattori T, Kuwabara S (2010) Neuronal activities of forebrain structures with respect to bladder contraction in cats. Neurosci Lett 473:42–47CrossRefPubMed

34.

Kitta T, Chancellor MB, de Groat WC, Shinohara N, Yoshimura N (2016) Role of the anterior cingulate cortex in the control of micturition reflex in a rat model of Parkinson’s disease. J Urol 195:1613–1620CrossRefPubMed

35.

Uchiyama T, Sakakibara R, Yoshiyama M, Yamamoto T, Ito T, Liu Z, Yamaguchi C, Awa Y, Yano HM, Yanagisawa M, Yamanishi T, Hattori T, Kuwabara S (2009) Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats. Neuroscience 162:1333–1338CrossRefPubMed

36.

Brusa L, Petta F, Pisani A, Moschella V, Iani C, Stanzione P, Miano R, Finazzi-Agrò E (2007) Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology 68:1455–1459CrossRefPubMed

37.

Uchiyama T, Sakakibara R, Yamamoto T, Ito T, Yamaguchi C, Awa Y, Yano M, Yanagisawa M, Kobayashi M, Higuchi Y, Ichikawa T, Yamanishi T, Hattori T, Kuwabara S (2009) Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson’s disease. Mov Disord 24:2386–2390PubMed

38.

Brusa L, Musco S, Bernardi G, Iani C, Pierantozzi M, Stanzione P, Stefani A, Finazzi Agro’ E (2014) Rasagiline effect on bladder disturbances in early mild Parkinson’s disease patients. Parkinsonism Relat Disord 20:931–932CrossRefPubMed

39.

Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL, Non-Motor Working Group of the Parkinson Study Group (PSG) (2015) Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord 21:514–520CrossRefPubMed

40.

Sakakibara R, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2005) Preliminary communication: urodynamic assessment of donepezil hydrochloride in patients with Alzheimer’s disease. Neurourol Urodyn 24:273–275CrossRefPubMed

41.

Donnellan CA, Fook L, McDonald P, Playfer JR (1997) Oxybutynin and cognitive dysfunction. BMJ 315:1363–1364CrossRefPubMedPubMedCentral

42.

Sakakibara R, Hamano H, Yagi H (2014) Cognitive safety and overall tolerability of imidafenacin in clinical use: a long-term, open-label, post-marketing surveillance study. Low Urin Tract Symptoms 6:138–144CrossRefPubMed

43.

Sakakibara R, Ogata T, Uchiyama T, Kishi M, Ogawa E, Isaka S, Yuasa J, Yamamoto T, Ito T, Yamanishi T, Awa Y, Yamaguchi C, Takahashi O (2009) How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central AChE inhibitor, and propiverine, a peripheral muscarine receptor antagonist. J Am Geriatr Soc 57:1515–1517CrossRefPubMed

44.

Igawa Y, Michel MC (2013) Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol 386:177–183CrossRefPubMed

45.

Vaughan CP, Juncos JL, Burgio KL, Goode PS, Wolf RA, Johnson TM 2nd (2011) Behavioral therapy to treat urinary incontinence in Parkinson disease. Neurology 76:1631–1634CrossRefPubMed

46.

Ito T, Sakakibara R, Nakazawa K, Uchiyama T, Yamamoto T, Liu Z, Shimizu E, Hattori T (2006) Effects of electrical stimulation of the raphe area on the micturition reflex in cats. Neuroscience 142:1273–1280CrossRefPubMed

47.

Sakakibara R, Ito T, Uchiyama T, Awa Y, Yamaguchi C, Hattori T (2008) Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. Urol Int 81:335–339CrossRefPubMed

48.

Suchowersky O, Furtado S, Rohs G (1995) Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord 10:337–340CrossRefPubMed

49.

Finazzi-Agro E, Peppe A, d’Amico A, Petta F, Mazzone P, Stanzione P, Micali F, Caltagirone C (2003) Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson’s disease. J Urol 169:1388–1391CrossRefPubMed

50.

Herzog J, Weiss PH, Assmus A, Wefer B, Seif C, Braun PM, Pinsker MO, Herzog H, Volkmann J, Deuschl G, Fink GR (2008) Improved sensory gating of urinary bladder afferents in Parkinson’s disease following subthalamic stimulation. Brain 131:132–145CrossRefPubMed

51.

Kabay SC, Kabay S, Yucel M, Ozden H (2009) Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson’s disease. Neurourol Urodyn 28:62–67CrossRefPubMed

52.

Brusa L, Finazzi Agrò E, Petta F, Sciobica F, Torriero S, Lo Gerfo E, Iani C, Stanzione P, Koch G (2009) Effects of inhibitory rTMS on bladder function in Parkinson’s disease patients. Mov Disord 24:445–448CrossRefPubMed

53.

Kulaksizoglu H, Parman Y (2010) Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease. Parkinsonism Relat Disord 16:531–534CrossRefPubMed

54.

Soler R, Füllhase C, Hanson A, Campeau L, Santos C, Andersson KE (2012) Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol 187:1491–1497CrossRefPubMed

55.

Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, Parkinson’s Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society (2016) A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn 35:551–563CrossRefPubMed

56.

Yamamoto T, Sakakibara R, Uchiyama T, Liu Z, Ito T, Awa Y, Yamanishi T, Hattori T (2009) Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov Disord 24:972–978CrossRefPubMed

57.

Yamamoto T, Sakakibara R, Uchiyama T, Yamaguchi C, Nomura F, Ito T, Yanagisawa M, Yano M, Awa Y, Yamanishi T, Hattori T, Kuwabara S (2011) Pelvic organ dysfunction is more prevalent and severe in MSA-P compared to Parkinson’s disease. Neurourol Urodyn 30:102–107CrossRefPubMed

58.

Sakakibara R, Hattori T, Uchiyama T, Kita K, Asahina M, Suzuki A, Yamanishi T (2000) Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? J Neurol Neurosurg Psychiatry 68:65–69CrossRefPubMedPubMedCentral

59.

Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, Masliah E, Low P, Sandroni P, Trojanowski JQ, Ozelius L, Foroud T, North American Multiple System Atrophy Study Group (2005) The North American Multiple System Atrophy Study Group. J Neural Transm 112:1687–1694CrossRefPubMed

60.

Cykowski MD, Coon EA, Powell SZ, Jenkins SM, Benarroch EE, Low PA, Schmeichel AM, Parisi JE (2015) Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain 138:2293–2309CrossRefPubMedPubMedCentral

61.

Sakakibara R, Uchida Y, Uchiyama T, Yamanishi T, Hattori T (2004) Reduced cerebellar vermis activation in response to micturition in multiple system atrophy: 99mTc-labeled ECD SPECT study. Eur J Neurol 11:705–708CrossRefPubMed

62.

Yamamoto T, Asahina M, Yamanaka Y, Uchiyama T, Hirano S, Fuse M, Koga Y, Sakakibara R, Kuwabara S (2017) The utility of post-void residual volume versus sphincter electromyography to distinguish between multiple system atrophy and Parkinson’s disease. PLoS One 12:e0169405. https://doi.org/10.1371/journal.pone.0169405 (eCollection 2017) CrossRefPubMedPubMedCentral

63.

Ito T, Sakakibara R, Yasuda K, Yamamoto T, Uchiyama T, Liu Z, Yamanishi T, Awa Y, Yamamoto K, Hattori T (2006) Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 21:816–823CrossRefPubMed

64.

Yamamoto T, Sakakibara R, Uchiyama T, Yamaguchi C, Nomura F, Ito T, Yanagisawa M, Yano M, Awa Y, Yamanishi T, Hattori T, Kuwabara S (2012) Receiver operating characteristic analysis of sphincter electromyography for parkinsonian syndrome. Neurourol Urodyn 31:1128–1134CrossRefPubMed

65.

Paviour DC, Williams DC, Fowler CJ, Quinn NP, Lees AJ (2005) Is sphincter electromyography a helpful investigation in the diagnosis of multiple system atrophy? A retrospective study with pathological diagnosis. Mov Disord 20:1425–1430CrossRefPubMed

66.

Mashidori T, Yamanishi T, Yoshida K, Sakakibara R, Sakurai K, Hirata K (2007) Continuous urinary incontinence presenting as the initial symptoms demonstrating acontractile detrusor and intrinsic sphincter deficiency in multiple system atrophy. Int J Urol 14:972–974CrossRefPubMed

67.

Takahashi O, Sakakibara R, Tsunoyama K, Tateno F, Yano M, Sugiyama M, Uchiyama T, Yamamoto T, Awa Y, Yamaguchi C, Yamanishi T, Kishi M, Tsuyuzaki Y (2012) Do sacral/peripheral lesions contribute to detrusor-sphincter dyssynergia? LUTS 4:126–129PubMed

68.

Pramstaller PP, Wenning GK, Smith SJM, Beck RO, Quinn NP, Fowler CJ (1995) Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 580:618–621CrossRef

69.

Yamamoto T, Sakakibara R, Uchiyama T, Yamaguchi C, Ohno S, Nomura F, Yanagisawa M, Hattori T, Kuwabara S (2014) Time-dependent changes and gender differences in urinary dysfunction in patients with multiple system atrophy. Neurourol Urodyn 33:516–523CrossRefPubMed

70.

Mathias CJ, Fosbraey P, DaCosta DF, Thornley A, Bannister R (1986) The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. BMJ 293:353–356CrossRefPubMedPubMedCentral

71.

Sakakibara R, Matsuda S, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T (2003) The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res 13:106–108CrossRefPubMed

72.

Sakakibara R, Murakami E, Katagiri A, Hayakawa S, Uchiyama T, Yamamoto T, Hattori T (2007) Moxibustion, an alternative therapy, ameliorated disturbed circadian rhythm of plasma arginine vasopressin and urine output in multiple system atrophy. Intern Med 46:1015–1018CrossRefPubMed

73.

Sakakibara R, Hattori T, Uchiyama T, Suenaga T, Takahashi H, Yamanishi T, Egoshi K, Sekita N (2000) Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 79:191–195CrossRefPubMed

74.

Sakakibara R, Uchiyama T, Asahina M, Yoshiyama M, Yamanishi T, Hattori T (2003) Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin Auton Res 13:51–53CrossRefPubMed

75.

Yamamoto T, Sakakibara R, Yamanaka Y, Uchiyama T, Asahina M, Liu Z, Ito T, Koyama Y, Awa Y, Yamamoto K, Kinou M, Hattori T (2006) Pyridostigmine in autonomic failure: can we treat postural hypotension and bladder dysfunction with one drug? Clin Auton Res 16:296–298CrossRefPubMed

76.

Uchiyama T, Sakakibara R, Asahina M, Yamanishi T, Hattori T (2005) Post-micturitional hypotension in patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 76:186–190CrossRefPubMedPubMedCentral

77.

Komiyama T, Hirokawa T, Sato K, Oka A, Kamiguchi H, Nagata E, Sakura H, Otsuka K, Kobayashi H (2015) Relationship between human evolution and neutrally mediated syncope disclosed by the polymorphic sites of the adrenergic receptor gene α2B-AR. PLoS One 10:e0120788. https://doi.org/10.1371/journal.pone.0120788 CrossRefPubMedPubMedCentral

78.

Coon EA, Sletten DM, Suarez MD, Mandrekar JN, Ahlskog JE, Bower JH, Matsumoto JY, Silber MH, Benarroch EE, Fealey RD, Sandroni P, Low PA, Singer W (2015) Clinical features and autonomic testing predict survival in multiple system atrophy. Brain 138:3623–3631CrossRefPubMedPubMedCentral

Titel: Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management
verfasst von: Ryuji Sakakibara
Fuyuki Tateno
Tatsuya Yamamoto
Tomoyuki Uchiyama
Tomonori Yamanishi
Publikationsdatum: 09.11.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Autonomic Research / Ausgabe 1/2018
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI: https://doi.org/10.1007/s10286-017-0480-0

Neu in den Fachgebieten Neurologie und Psychiatrie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management

Abstract

Objective

Method

Results

Conclusions

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Method

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Autonomic dysfunction predicts poor outcome in stroke: Updates on recent autonomic research

Abstracts of the 6th international multiple system atrophy congress

Infectious diseases causing autonomic dysfunction

Neurogenic dysphagia with undigested macaroni and megaesophagus in familial dysautonomia

Acute onset autonomic dysfunction and orthostatic syncope as an early manifestation of HIV infection

The endocannabinoid system in cardiovascular function: novel insights and clinical implications

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen